GlassScriptPhysician profile
Catherine Miranda
NPI 1497045942
$2,249.60
in general payments reported to CMS, 2019-2025
18 companies · $839 in 2025
The $839 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $349 · 2023: $314 · 2024: $748 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,900.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $527.28 | 2022-2025 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $389.59 | 2024-2025 | |
| Amgen INC. | $239.51 | 2024-2025 | Krystexxa, Tavneos |
| Novartis Pharmaceuticals Corporation | $214.39 | 2023-2025 | |
| Vifor Pharma, INC. | $168.96 | 2023-2025 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $138.80 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $136.82 | 2022-2025 | Jynarque |
| Ardelyx, INC. | $105.16 | 2024-2025 | Ibsrela |
| Abbvie INC. | $68.92 | 2022-2024 | |
| Genzyme Corporation | $48.08 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.45 | 2024 | Jardiance |
| Glaxosmithkline, LLC. | $39.25 | 2022 | |
| Novo Nordisk INC | $25.44 | 2025 | Ozempic |
| Fresenius USA Manufacturing, INC. | $23.49 | 2025 | |
| Lilly USA, LLC | $23.37 | 2025 | Jardiance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $23.20 | 2024 | Velphoro |
| Daiichi Sankyo INC. | $18.50 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.39 | 2024 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Miranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.